Dual-Targeted Peptide Nanoparticles for Nasopharyngeal Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nasopharyngeal carcinoma, such as radiotherapy and chemotherapy, have limitations including toxicity, limited effectiveness for distant metastases, and high costs, while monoclonal antibodies face challenges with immunogenicity and poor penetration, necessitating a more targeted and effective therapeutic approach.
Innovation Solution
Development of a dual-targeted therapeutic peptide (dtTPNPC) linked via a peptide linker, encapsulated in ultra-small lipid nanoparticles with a phospholipid and cholesteryl ester shell, loaded with an imaging contrast agent and chemotherapy drugs like paclitaxel or curcumin, to enhance targeting and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used as targeting molecules, then tumor targeting ability is improved, but immunogenicity increases and production cost increases
Solution Approach 1:
The patent replaces expensive monoclonal antibodies with short peptides (6-20 amino acids) that have low immunogenicity and low production cost. The peptides are designed to specifically bind to tumor cell surface receptors, providing the necessary targeting ability without the drawbacks of antibody-based approaches.
Solution Approach 2:
The patent changes the molecular weight parameter from large monoclonal antibodies to small peptides, and uses multivalent display on nanoparticle surfaces to compensate for the lower individual binding affinity, achieving effective tumor targeting through increased local concentration and avidity effects.
2Reliability
If monoclonal antibodies are used for tumor treatment, then targeting specific lethal role is achieved, but penetration into large volume solid tumor decreases due to large molecular weight
Solution Approach 1:
The patent segments the targeting function from the therapeutic function. Small peptides provide the targeting function by binding to tumor surface receptors, while the actual therapeutic agents (chemotherapy drugs, radionuclides, or toxins) are carried on the nanoparticle surface or inside, enabling both targeting and effective treatment.
Solution Approach 2:
The patent uses nanoparticle carriers as intermediaries that bridge the gap between small peptides and large therapeutic agents. The nanoparticles display multiple peptide ligands on their surface for tumor targeting while carrying therapeutic payloads, solving the penetration problem by using the EPR effect for tumor accumulation.
3Reliability
If traditional radiotherapy and chemotherapy are used, then treatment coverage includes primary tumor and sentinel lymph nodes, but toxic side effects increase and distant metastasis treatment is limited
Solution Approach 1:
The patent employs passive targeting through the EPR (enhanced permeability and retention) effect, where the nanoparticle system automatically accumulates in tumor tissue due to the unique physiological characteristics of tumors (leaky vasculature and poor lymphatic drainage), eliminating the need for active targeting mechanisms and reducing immunogenicity concerns.
Solution Approach 2:
The patent extracts the targeting function from system-wide chemotherapy and concentrates it at the tumor site through nanoparticle-mediated delivery. This allows the therapeutic agents to be delivered systemically while achieving localized concentration at the tumor, treating both primary tumors and distant metastases while reducing off-target toxicity.
4Measurement precision
If far-red fluorescent protein is used in nano-probe, then tumor-targeting property and biological anti-tumor effect can be screened accurately, but immunogenicity increases due to foreign protein
Solution Approach 1:
The patent extracts only the essential targeting peptide sequence from the far-red fluorescent protein nano-probe and transfers it to a nanoparticle carrier system. This removes the immunogenic foreign protein components while retaining the tumor-specific targeting capability of the peptide ligand.
Solution Approach 2:
The patent copies the targeting function from the fluorescent protein nano-probe to a simplified nanoparticle system. The peptide sequence responsible for tumor binding is identified and replicated on the nanoparticle surface, eliminating the need for the complex fluorescent protein structure and its associated immunogenicity.
Data Source
AI summary
Disclosed is a dual-targeted therapeutic peptide for nasopharyngeal carcinoma formed by covalently linking a targeted therapeutic peptide for nasopharyngeal carcinoma, a peptide linker and a targeted therapeutic peptide with an α-helical structure for nasopharyngeal carcinoma. Also disclosed is a nanoparticle containing the peptide. The peptide and the nanoparticle can be used to treat nasopharyngeal carcinoma.